Ratings Surperformance

Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
BBB
Ratings Surperformance© - Intra-Cellular Therapies, Inc.

Ratings ESG MSCI

Ratings ESG MSCI - Intra-Cellular Therapies, Inc.

Ratings Intra-Cellular Therapies, Inc.: Strengths and Weaknesses

  • The company's MSCI ESG score, based on a relative ranking of the company within its sector, comes out particularly poor.

Rating Financials

Intra-Cellular Therapies, Inc. SectorUnited States

Fundamentals

-

Growth

-

Revenue growth

-

EPS growth

-

FCF growth

-

Profitability

-

EBITDA Margin

-

EBIT Margin

-

Net Margin

-

Capital Efficiency

-

ROA

-

ROCE

-

ROE

-

Financial Health

-

Gearing

-

Leverage

-

Capital Intensity

-

Balance sheet growth

-

Long Term balance sheet growth

-

Long term revenue growth

-

Long term EPS growth

-
More ratings
Fundamental Rankings - Intra-Cellular Therapies, Inc.

Rating Valuation

Intra-Cellular Therapies, Inc. SectorUnited States

Global Valuation

-

Enterprise Value

-

EV/Revenue

-

EV/EBITDA

-

EV/FCF

-

Equity Valuation

-

P/E

-

PBR

-

Dividend Yield

-

EV/EBIT

-

CAPEX/Revenue

-
More ratings
Fundamental Rankings - Intra-Cellular Therapies, Inc.

Rating Consensus

Intra-Cellular Therapies, Inc. SectorUnited States

Consensus

Analysts' buy/sell recommendations

-

Analysts' recommendations evolution (1 year)

Analysts' recommendations evolution (4 months)

Analysts' target price

-

Analysts' target price evolution (1 year)

Analysts' target price evolution (4 months)

Analysts' recommendations evolution (7 days)

Target Price evolution (7 days)

More ratings
Fundamental Rankings - Intra-Cellular Therapies, Inc.

Rating Business Predictability

Intra-Cellular Therapies, Inc. SectorUnited States

Visibility

-

Analysts' coverage

-

Financial estimates divergence

-

Analysts' recommendations divergence

-

Analysts' Target price divergence

-

Surprise rates

Fundamental Rankings - Intra-Cellular Therapies, Inc.

Rating Revisions

Intra-Cellular Therapies, Inc. SectorUnited States

Financial revisions

Revenue revisions (1 year)

Revenue revisions (4 months)

EPS revisions (1 year)

EPS revisions (4 months)

EPS revisions (7 days)

Revenue revisions (7 days)

More ratings
Fundamental Rankings - Intra-Cellular Therapies, Inc.


Capi.($) Investor ESG MSCI Fundamentals Financial revisions Global Valuation Visibility Consensus
14.02B -
BBB
- - -
1,060B
A
623B
BBB
480B
AAA
-
352B
AA
345B
AA
274B
AAA
249B
A
223B
BBB
182B
AA
Average 380.2B
AA
Weighted average by Cap.
AA
  1. Stock Market
  2. Stocks
  3. ITCI Stock
  4. Ratings Intra-Cellular Therapies, Inc.